<code id='1CDC384634'></code><style id='1CDC384634'></style>
      • <acronym id='1CDC384634'></acronym>
      <center id='1CDC384634'><center id='1CDC384634'><tfoot id='1CDC384634'></tfoot></center><abbr id='1CDC384634'><dir id='1CDC384634'><tfoot id='1CDC384634'></tfoot><noframes id='1CDC384634'>
      • <optgroup id='1CDC384634'><strike id='1CDC384634'><sup id='1CDC384634'></sup></strike><code id='1CDC384634'></code></optgroup>
        5. <b id='1CDC384634'><label id='1CDC384634'><select id='1CDC384634'><dt id='1CDC384634'><span id='1CDC384634'></span></dt></select></label></b><u id='1CDC384634'></u>
          <i id='1CDC384634'><strike id='1CDC384634'><tt id='1CDC384634'><pre id='1CDC384634'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / explore / focus      
           
     
           
      
          focus 
           
      
           
      
           
       2025-10-05 03:30:23 
   
      
           
      
           
                        
          focus  
          
                                   
                 
                                      author：knowledge   
                                        
                                      
                                      Page View：4
                                  
                                    
          
                                   
          close-up of psoriasis on a hand. -- biotech coverage from STAT
          A close-up of psoriasis on a hand.																									Adobe 
          San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.
          Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.
          advertisement
          Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Rep. Raul Ruiz on the physician shortage and more
                                
                            
          Next article：  
                                      
                                          The cancer drug shortage isn’t new — and neither are the solutions
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles